{
    "id": 24791,
    "fullName": "MTOR M2327I",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MTOR M2327I lies within the PI3K/PI4K domain of the Mtor protein (UniProt.org). M2327I confers a gain of function to the Mtor protein as demonstrated by increased kinase activity compared to wild-type and increased phosphorylation of S6K and AKT (PMID: 27279227).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2475,
        "geneSymbol": "MTOR",
        "terms": [
            "MTOR",
            "FRAP",
            "FRAP1",
            "FRAP2",
            "RAFT1",
            "RAPT1",
            "SKS"
        ]
    },
    "variant": "M2327I",
    "createDate": "07/26/2016",
    "updateDate": "08/02/2016",
    "referenceTranscriptCoordinates": {
        "id": 145340,
        "transcript": "NM_004958",
        "gDna": "chr1:g.11117039C>G",
        "cDna": "c.6981G>C",
        "protein": "p.M2327I",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7499,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line expressing MTOR M2327I demonstrated sensitivity to treatment with Rapamune (sirolimus) in xenograft models, resulting in decreased tumor volume (PMID: 27279227).",
            "molecularProfile": {
                "id": 25548,
                "profileName": "MTOR M2327I"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7500,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line expressing MTOR M2327I demonstrated sensitivity to treatment with RapaLink-1 in xenograft models, resulting in decreased tumor volume (PMID: 27279227).",
            "molecularProfile": {
                "id": 25548,
                "profileName": "MTOR M2327I"
            },
            "therapy": {
                "id": 4493,
                "therapyName": "RapaLink-1",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7489,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cells demonstrated resistance to AZD8055 after three months of treatment in culture due to the acquired resistance mutation, MTOR M2327I (PMID: 27279227).",
            "molecularProfile": {
                "id": 25548,
                "profileName": "MTOR M2327I"
            },
            "therapy": {
                "id": 1519,
                "therapyName": "AZD8055",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7494,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line expressing both MTOR F2108L and MTOR M2327I demonstrated resistance to treatment with Rapamune (sirolimus) in culture (PMID: 27279227).",
            "molecularProfile": {
                "id": 25591,
                "profileName": "MTOR F2108L MTOR M2327I"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7493,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line expressing both MTOR F2108L and MTOR M2327I demonstrated sensitivity to treatment with RapaLink-1 in culture, resulting in inhibition of Mtor and downstream signaling (PMID: 27279227).",
            "molecularProfile": {
                "id": 25591,
                "profileName": "MTOR F2108L MTOR M2327I"
            },
            "therapy": {
                "id": 4493,
                "therapyName": "RapaLink-1",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7495,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line expressing both MTOR F2108L and MTOR M2327I demonstrated resistance to treatment with Sapanisertib (MLN0128) in culture (PMID: 27279227).",
            "molecularProfile": {
                "id": 25591,
                "profileName": "MTOR F2108L MTOR M2327I"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7496,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line expressing both MTOR F2108L and MTOR M2327I demonstrated resistance to the combination treatment of Rapamune (sirolimus) and Sapanisertib (MLN0128) in culture (PMID: 27279227).",
            "molecularProfile": {
                "id": 25591,
                "profileName": "MTOR F2108L MTOR M2327I"
            },
            "therapy": {
                "id": 4497,
                "therapyName": "Sapanisertib + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25548,
            "profileName": "MTOR M2327I",
            "profileTreatmentApproaches": [
                {
                    "id": 10798,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "MTOR M2327I"
                },
                {
                    "id": 10797,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "MTOR M2327I"
                },
                {
                    "id": 10796,
                    "name": "mTOR Inhibitor",
                    "profileName": "MTOR M2327I"
                }
            ]
        },
        {
            "id": 25591,
            "profileName": "MTOR F2108L MTOR M2327I",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 145340,
            "transcript": "NM_004958",
            "gDna": "chr1:g.11117039C>G",
            "cDna": "c.6981G>C",
            "protein": "p.M2327I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 145341,
            "transcript": "XM_005263438",
            "gDna": "chr1:g.11117039C>G",
            "cDna": "c.6981G>C",
            "protein": "p.M2327I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}